Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica Remedia Total Payout Ratio Related Terms
Farmaceutica Remedia Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, COR, CAH: Total Payout Ratio Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Total Payout Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farmaceutica Remedia (BSE:RMAH) has a Total Payout Ratio of 0.00 as of Sep. 22, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Total Payout Ratio too high?
Farmaceutica Remedia's current Total Payout Ratio is 0.00. Overall, Farmaceutica Remedia has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Total Payout Ratio compare to MCK and COR?
Farmaceutica Remedia's Total Payout Ratio of 0.00 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Distribution company?
A good Total Payout Ratio depends on the Medical Distribution industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Modestly Undervalued. The stock's GF Value™ is lei0.85, compared to a current price of lei0.75 — trading 11.8% below its estimated fair value. The current Total Payout Ratio is 0.00. Farmaceutica Remedia's overall GF Score™ is 61/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Total Payout Ratio is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be undervalued.
The current stock price of lei0.75 is trading 11.8% below its estimated GF Value™ of lei0.85.
GuruFocus considers Farmaceutica Remedia to be Modestly Undervalued.
Key valuation signals for BSE:RMAH:
Total Payout Ratio: 0.00
GF Value™: lei0.85 vs. price of lei0.75 (11.8% below fair value)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is a Romanian pharmaceutical distribution and marketing company. It operates through two main segments: distribution, supplying medicines, dietary supplements, cosmetics, and medical devices to pharmacies, hospitals, and other healthcare providers; and marketing and promotion services for pharmaceutical manufacturers seeking to launch or expand products in Romania. Its logistics operations include warehousing, order fulfillment, and nationwide delivery, while its medical marketing arm offers product registration, regulatory support, and sales force services. The company serves both domestic and international pharmaceutical producers, acting as a distribution partner across Romania and other Eastern European markets. Revenue is generated primarily from wholesale drug distribution, supplemented by fees for marketing, promotion, and logistics services. Farmaceutica Remedia is headquartered in Deva, Romania, and its shares are listed on the Bucharest Stock Exchange.
61GF Score
Get the complete analysis for BSE:RMAH
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
